In conclusion, this research demonstrates that in patients living with PBC, whether untreated or receiving first-line therapy, elevations in ALP, TB, AST and ALT and reduction in albumin levels beyond guideline-recommended thresholds are predictive of negative clinical outcomes. The gene discussed is ALB; the disease is primary biliary cholangitis.